Ciprofloxacin injections for treating skin leishmaniasis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial evaluates the effectiveness of intralesional ciprofloxacin 0.2% solution as a treatment for cutaneous leishmaniasis, comparing it to the standard treatment of intralesional sodium stibogluconate (SSG) 10%. Patients are randomly assigned to receive either ciprofloxacin or SSG injections, with each lesion treated as a separate case. The lesions will be monitored for 90 days or until they are cured to assess the treatment outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with single or multiple (less than seven lesions) lesions of cutaneous leishmaniasis

Exclusion Criteria:

* Patients who received anti-leishmaniasis treatment locally or systemically for the last month before this study
* patients on prolonged corticosteroid therapy.

Where it's running

• Mustansiriyah University
  Baghdad, Iraq Recruiting

Study contacts

• Study coordinator: Hayder Adnan Fawzi, PhD
• Email: haider-pharm@almustafauniversity.edu.iq
• Phone: 009647800106177

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using metronidazole injections to treat skin lesions from leishmaniasis

  This study is testing if weekly injections of metronidazole can help people with skin lesions from leishmaniasis heal faster.

  Recruiting Phase 2 Al-Mustafa University College · Baghdad · NCT06798415

• Using levofloxacin injections to treat skin leishmaniasis

  This study is testing if weekly injections of levofloxacin can effectively treat skin leishmaniasis in patients with localized lesions.

  Recruiting Phase 2 Al-Mustafa University College · Baghdad · NCT06797544

• Using thermotherapy at health centers to treat skin leishmaniasis in Ethiopia

  This study tests whether thermotherapy using the ThermoMed device can be feasibly used in primary care to treat cutaneous leishmaniasis in Ethiopia and sees how well it works for people in the Sodo area.

  Recruiting Armauer Hansen Research Institute, Ethiopia · Addis Ababa · NCT06746350

• Immunogenicity screening of Leishmania vaccine candidate antigens in Ethiopian patients

  This study tests whether six Leishmania vaccine candidate antigens can trigger T-cell responses in patients with cutaneous or visceral leishmaniasis.

  Recruiting at 2 sites Institute of Tropical Medicine, Belgium · Addis Ababa and 1 other locations · NCT07783243

• Pediatric leishmaniasis in Italy: clinical and treatment patterns

  This project will collect medical information to see how leishmaniasis presents and is treated in children under 18 in Italy.

  Recruiting Meyer Children's Hospital IRCCS · Florence, Tuscany · NCT07504757

• Arnica tincture for treating cutaneous leishmaniasis

  This test will see if applying arnica tincture to skin lesions helps heal cutaneous leishmaniasis in people aged 12 and older.

  Recruiting Phase 3 Universidad de Antioquia · Medellín, Antioquia · NCT06822478

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.